top of page

enGenes to Present Breakthrough Continuous Bioprocessing Technology at Bioprocessing Summit Boston

  • opheliagevaert1
  • Aug 6
  • 2 min read

Updated: Aug 7

Vienna, Austria: – Five months after attending the European BioProcess Summit in Barcelona, recombinant proteins and plasmid DNA specialist CDMO enGenes Biotech will also be a high-profile presence at the USA sister event, the 2025 Bioprocessing Summit in Boston.

This is the first time enGenes has attended the linked summits on both sides of the Atlantic in a single year, partly reflecting its growing influence on bioprocessing science and technology with its patented expression and purification platforms and its leading role in the strategically vital move towards continuous production of proteins and plasmid DNA (pDNA).


Scientific contributor

enGenes CEO and co-founder Dr. Juergen Mairhofer will contribute to the scientific program as part of the conference track on Continuous and Intensive Bioprocessing chaired by Professor David W. Wood of Ohio State University during the first two days (August 18-19).

During the afternoon session of the first day, Dr. Mairhofer will make a presentation on “Fully End-to-End Continuous Production of Recombinant Proteins using E. coli” that will introduce the vital role of the enGenes-eXpress™ growth-decoupled expression platform that provides the foundation for a two-stage chemostat that  is genetically stabilized and mitigates adaptive evolution. This two stage chemostat can then be exploited by enGenes-eXcite™ as a cutting-edge technology that further supports continuous manufacturing of biomolecules in E. coli by enabling high yields and scalability from a very small footprint.


High yield and scalability

Dr. Mairhofer will show how these technologies enable sustained, high-yield recombinant protein production while reducing operational footprint, CAPEX, and OPEX and outperforming traditional fed-batch methods. This makes continuous protein production viable for biopharma and industrial biotech, thereby transforming efficiency and scalability.


He will also highlight the advantages gained by combining advanced expression with leading edge machine intelligence modelling and advanced automated real-time process monitoring in the recent ECOnti Project that has achieved significant progress towards continuous protein manufacturing. EnGenes has reunited with ECOnti project partners novasign® and Qubicon® AG in the iCAP Project (Integrated Continuous and Automated Platform for Plasmid Production) looking to revolutionize manufacturing of pDNA.




ree

 
 
 

Comments

bottom of page